AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a Redwood City-based specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, is to acquire Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company using its proprietary chemistry technology to develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by many multidrug-resistant, or MDR, bacteria.

The CVR represents additional consideration upon XERAVA™ (eravacycline for injection) achieving certain net sales starting in 2021.

The transaction – unanimously approved by both the AcelRx and Tetraphase Boards of Directors – is expected to close in the second quarter of 2020, subject to customary closing conditions.

Led by Vince Angotti, Chief Executive Officer, AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions.

Led by Larry Edwards, President and Chief Executive Officer, Tetraphase Pharmaceuticals is a biopharmaceutical company using its proprietary chemistry technology to develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by many multidrug-resistant, or MDR, bacteria. | To read full story, visit https://startuparound.com/read/1584399610.789895/AcelRx-Pharmaceuticals-to-Acquire-Tetraphase-Pharmaceuticals?ref=audio_experience